Related Experiment Videos
[Experimental and clinical studies of sulbactam/cefoperazone in pediatric field]
Insights
Sulbactam/cefoperazone (SBT/CPZ) demonstrated high efficacy in pediatric infections, with an 87.9% overall success rate. This antibiotic combination showed particular effectiveness against beta-lactamase producing organisms in urinary tract infections.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Context:
- Pediatric infections pose significant health challenges.
- Beta-lactamase producing organisms are a growing concern in treating bacterial infections.
- Effective antimicrobial options are crucial for pediatric patient outcomes.
Purpose:
- To evaluate the efficacy and pharmacokinetics of sulbactam/cefoperazone (SBT/CPZ) in pediatric patients.
- To assess the safety profile of SBT/CPZ in this population.
- To determine the effectiveness of SBT/CPZ against specific pediatric infections, including those caused by beta-lactamase producing bacteria.
Summary:
- Sulbactam/cefoperazone (SBT/CPZ) was administered to 33 pediatric patients with infections, including respiratory tract, urinary tract, and Salmonella enterocolitis.
- The combination showed a mean serum half-life of 0.7 hours for sulbactam and 1.2 hours for cefoperazone.
- An overall efficacy rate of 87.9% was observed, with notable success in treating 7 out of 8 urinary tract infections caused by beta-lactamase producing organisms.
Impact:
- SBT/CPZ offers a promising therapeutic option for various pediatric infections.
- The study highlights the potential of SBT/CPZ in combating infections caused by resistant bacterial strains.
- Understanding the pharmacokinetic and efficacy data aids in optimizing antimicrobial stewardship in pediatric care.
Abstract:
Clinical trials were carried out with sulbactam/cefoperazone (SBT/CPZ) (combination ratio of 1:1) in pediatric infections. Results were as follows. The mean half-lives of SBT and CPZ in the serum following intravenous injection of SBT/CPZ were about 0.7 and 1.2 hours, respectively. Urinary excretions of SBT and CPZ within 6 hours after intravenous injection of SBT/CPZ were 81.9% and 28.1%, respectively. SBT/CPZ was administered to 33 pediatric patients with various infection; 18 respiratory tract infections, 12 urinary tract infections and 3 Salmonella enterocolitis. The overall efficacy rate was 87.9%. In particular, 7 of 8 urinary tract infections caused by beta-lactamase producing organisms were improved after administration of SBT/CPZ. Diarrhea in 8 and soft stool in 3 of 33 patients occurred, and slight elevation of GOT/GPT was observed in 2 patients.